Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653832 | 0.84 | ADORA2A (0.53) | ADORA2AADORA2BADORA1ADORA3KDM4E | |
| SCHEMBL12995597 | 0.81 | ADORA2A (0.66) | ADORA2AADORA2BADORA1ADORA3VNN1 | |
| SCHEMBL6214643 | 0.79 | ADORA2A (0.75) | ADORA2AADORA2BADORA1 | |
| SCHEMBL3655720 | 0.74 | ADORA2A (0.41) | ADORA2AADORA1KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL3660611 | 0.65 | ADORA2B (0.64) | ADORA2AADORA2BADORA3KDM4EHSD17B10 | |
| SCHEMBL20784504 | 0.65 | ADORA2A (1.00) | ADORA2AADORA2BADORA3 | |
| SCHEMBL20119610 | 0.65 | JAK2 (0.51) | KDM4EHSD17B10ALDH1A1GBA1MAPT | |
| SCHEMBL12046053 | 0.65 | SMN1; SMN2 (0.57) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL30770799 | 0.64 | MAOA (0.56) | ADORA2AADORA2BKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL6858372 | 0.63 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305143-A1 | PYRROLOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2010-12-02 | — | — | US | disclosed |
| US-20100305143-A1 | PYRROLOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2010-12-02 | — | — | US | disclosed |
| US-20100305143-A1 | PYRROLOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2010-12-02 | — | — | US | disclosed |
| EP-2203452-A1 | PYRROLOPYRIMIDINE COMPOUNDS | Vernalis (R&D) Ltd. (GB) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037467-A1 | PYRROLOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305143-A1 | PYRROLOPYRIMIDINE COMPOUNDS | ADORA2B, CNR2, CNR1 | ADORA2A 15/4885ADORA2B 1/4885ADORA1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.